Remedent, Inc. Reports 2005 Year-End Results; Revenue Increased 4.5% Year-Over-Year

Remedent, Inc. (OTC BB: REMI) a leader in the research
and development, manufacturing and marketing of oral care and cosmetic
dentistry products, announced today its year-end results for the year
ended March 31, 2006.
   Remedent announced that net sales for the year ended March 31,
2006 increased 4.5% to $7.4 million from $7.1 million for the year
ended March 31, 2005. The increase in sales is attributed to
continuing sales efforts and the initial market acceptance of the
iWhite(R) and MetaTray(R) products.
   Gross profit declined 12% to $3.6 million for the year ended March
31, 2006, compared to $4.1 million. The decline was due to the rise of
cost of goods and the reduced margins on the Remecure products,
resulting from a 28% reduction in average selling price of Remecure
products to meet competitive demands. The company experienced delays
in the in-house manufacturing of foam strips and regulatory approvals
in certain countries. These issues have been resolved and will not
affect the future business.
   Net loss for the year was $3.9 million, or $0.35 per fully diluted
share, in the year ended March 31, 2006 compared to a loss of $104,000
in the preceding year, or $0.05 per fully diluted share.
   The company was also impacted by the cost associated with the
start-up of new Singapore and US sales offices, which accounted for
approximately $1.0 million of the $3.9 million of net loss. In
addition, the company purchased the royalty agreement of its top
product, along with expenses related to the offering and options to
the investment banker, which combined for $2.0 million of the net
loss.
   Guy De Vreese, Chairman of Remedent, stated, "We are pleased in
the top-line growth of Remedent. All of revenues last year came from
European markets, which highlights the strength of our brand
recognition in Europe, which we are also building in Asia. As we
continue to strengthen our global footprint, our efforts will be
selective in the US markets to maintain acceptable cost levels. Our
goal is to ensure that we have a strong market presence in the US."
   He added, "We are excited at the potential of the brand
recognition and believe that Remedent will have a global presence. Our
partners in Europe have given us the assurance of their commitment to
selling the Remedent products, and we want to be their customers'
first choice product."
   Remedent, Inc. (OTC Bulletin Board: REMI) strives to be a world
leader in the research and development, manufacturing and marketing of
oral care and cosmetic dentistry products. Remedent products are
renowned for their technological superiority and ease-of-use. Based in
Deurle, Belgium and El Segundo, CA, Remedent has successfully
researched, developed and manufactured all of its own products. These
products are now distributed in more than 35 countries worldwide.
Remedent consists of two divisions: one that serves the dental
community and one that is focused on the over-the-counter consumer
market. Visit www.Metatray.com/usa for further information.
-0-
*T

                    REMEDENT, INC. AND SUBSIDIARIES
                      CONSOLIDATED BALANCE SHEETS

                                                 March 31,   March 31,
                                                   2006        2005
                                               ----------- -----------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents                        $332,145     $40,442
Cash, restricted                                   70,762           -
  Accounts receivable, net of allowance for
  doubtful accounts of $74,133 at March 31,
  2006 and $80,194 at March 31, 2005            2,370,846   1,488,296
Due from related party                                  -     156,099
Inventories, net                                1,470,553     558,335
Prepaid expense                                   335,111     192,306
Other current assets                                    -     129,650
                                               ----------- -----------
Total current assets                            4,579,417   2,565,128
                                               ----------- -----------
PROPERTY AND EQUIPMENT, NET                       317,361      85,737
OTHER ASSETS
Deferred offering costs                                 -
Patents, net                                      166,166      61,750
                                               ----------- -----------
                                                  166,166      61,750
                                               ----------- -----------
TOTAL ASSETS                                   $5,062,944  $2,712,615
                                               =========== ===========

LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES:
Current portion, long term debt                   $12,641          $-
Line of Credit                                    605,200           -
Notes payable                                      31,282     294,322
Accounts payable                                1,632,449     889,668
Accrued liabilities                               601,042     367,854
Due to related parties                             58,958      58,958
Deferred revenue                                        -      18,864
Income taxes payable                              103,001     178,269
                                               ----------- -----------
Total current liabilities                       3,044,573   1,807,935
                                               ----------- -----------
LONG TERM DEBT                                     60,998           -
MINORITY INTEREST IN REMEDENT N.V.                      -   1,178,592
STOCKHOLDERS' DEFICIT:
  Preferred Stock $0.001 par value (10,000,000
  shares authorized, none issued and
  outstanding)                                          -           -
  Common stock, $0.001 par value; (50,000,000
  shares authorized, 12,764,112 shares issued
  and outstanding at March 31, 2006 and
  2,176,225 shares issued and outstanding at
  March 31, 2005)                                  12,764       2,176
Additional paid-in capital                     11,624,234   5,427,289
Accumulated deficit                            (9,651,551) (5,764,249)
Common stock subscribed, not issued                   200           -
Accumulated other comprehensive income (loss)
(foreign currency translation adjustment)         (28,274)     60,874
                                               ----------- -----------
Total stockholders' equity (deficit)            1,957,373    (273,910)
                                               ----------- -----------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
(DEFICIT)                                      $5,062,944  $2,712,615
                                               =========== ===========

              The accompanying notes are an integral part
              of these consolidated financial statements.

                    REMEDENT, INC. AND SUBSIDIARIES
                 CONSOLIDATED STATEMENTS OF OPERATIONS

                                                For the years ended
                                                     March 31,
                                                  2006         2005
                                              ------------ -----------
Net sales                                      $7,393,948  $7,072,300
Cost of sales                                   3,812,463   2,982,315
                                              ------------ -----------
 Gross profit                                   3,581,485   4,089,985
Operating Expenses
  Research and development                      1,153,897     263,137
  Sales and marketing                           1,202,145     325,175
  General and administrative                    4,235,292   2,578,274
  Non cash restructuring expense                  764,151           -
  Depreciation and amortization                   107,222      35,636
                                              ------------ -----------
 TOTAL OPERATING EXPENSES                       7,462,707   3,202,222
                                              ------------ -----------
INCOME (LOSS) FROM OPERATIONS                  (3,881,222)    887,763
OTHER INCOME (EXPENSES)
  Interest expense                                (24,195)    (66,390)
  Non cash interest expense                      (100,000)          -
  Other income                                     49,427      25,544
                                              ------------ -----------
 TOTAL OTHER INCOME (EXPENSES)                    (74,768)    (40,846)
                                              ------------ -----------
INCOME (LOSS) BEFORE INCOME TAXES AND
MINORITY INTEREST                              (3,955,990)    846,917
Income tax (expense) benefit                       68,688    (363,072)
MINORITY INTEREST IN REMEDENT N.V.                      -    (587,273)
                                              ------------ -----------
NET LOSS                                      $(3,887,302)  $(103,428)
                                            ==========================
LOSS PER SHARE
 Basic and fully diluted                           $(0.35)     $(0.05)
                                            ==========================
WEIGHTED AVERAGE SHARES OUTSTANDING
 Basic and fully diluted                       11,122,754   2,047,470
                                            ==========================

*T

   Certain matters discussed in this press release are
"forward-looking statements" intended to qualify for the safe harbors
from liability established by the Private Securities Litigation Reform
Act of 1995. In particular, the Company's statements regarding trends
in the marketplace and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
consummation and the successful integration of proposed acquisitions,
the timing of projects due to the variability in size, scope and
duration of projects, estimates made by management with respect to the
Company's financial results, backlog, critical accounting policies,
regulatory delays, clinical study results which lead to reductions or
cancellations of projects, and other factors, including general
economic conditions and regulatory developments, not within the
Company's control. The factors discussed herein and expressed from
time to time in the Company's filings with the Securities and Exchange
Commission could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent
events or circumstance.